Futura Medical shares rise on ED licensing deal with Haleon
Futura Medical
32.25p
16:30 23/12/24
0.94%
0.30p
Shares in Futura Medical gained on Monday after the company said it signed a licensing deal with consumer heath care giant Haleon for the rights to exclusively commercialise its topical, gel-based erectile dysfunction treatment MED3000 in the USA.
FTSE 100
8,096.53
16:34 23/12/24
n/a
n/a
FTSE 350
4,467.61
16:30 23/12/24
n/a
n/a
FTSE AIM All-Share
712.05
16:34 23/12/24
n/a
n/a
FTSE All-Share
4,425.27
16:30 23/12/24
n/a
n/a
Haleon
380.20p
16:35 23/12/24
-0.24%
-0.90p
Pharmaceuticals & Biotechnology
19,983.75
16:29 23/12/24
1.13%
222.63
Futura will receive an initial upfront payment of $4m, royalty payments on all sales of MED3000 by Haleon and potential commercial and performance-driven sales milestone payments totalling between $5m and $45m payable over the course of several years